-
After the announcement of the results of the collection of artificial joints, the stock prices of many machinery companies fluctuated
Time of Update: 2021-10-01
Specifically, 44 of the 48 companies that participated in the centralized procurement quotation were selected, and more than 140 products received the "entry ticket" for the centralized procurement, including import manufacturers Johnson & Johnson, Xerox Hui, Shi Sai g, as well as leading domestic Weigao orthopedic, Icahn medical, Chun-li and medical .
-
In 2021 ESMO domestic pharmaceutical companies were selected for oral reports with more than ten Cinda and 2 cornerstones each
Time of Update: 2021-10-01
The 2021 European Society of Medical Oncology (ESMO) annual meeting officially opened on September 16, local time . The current annual meeting will last six days and will be held online . The resu
-
The high-quality development of the biopharmaceutical industry requires continued assistance from pharmaceutical companies
Time of Update: 2021-10-01
In June this year, Henan Province also issued the "Measures to Promote the High-Quality Development of the Biomedical Industry in Our Province" to help serve biomedicine in many aspects such as optimizing the review mechanism, supporting the development of the pharmaceutical industry park, and improving the review and inspection.
-
Why is there a wave of mergers and acquisitions in the medical device industry in 2021?
Time of Update: 2021-10-01
However, in recent years, as competition in the medical device industry has intensified, the volume procurement policy under medical insurance control fees has put pressure on mature businesses for growth; coupled with the acceleration of product iteration in the medical device field, various factors have brought huge challenges to medical device companies.
-
The domestic CRO development momentum continues to be strong, showing two major development trends
Time of Update: 2021-10-01
From an overall point of view, the industry believes that domestic CRO companies are gradually occupying an advantageous position in the global innovative drug industry chain transfer wave, and ushering in more benefits, relying on the advantages of engineer dividends and integrated platform services .
-
A chain pharmacy in Changchun, Jilin was fined 220,000 yuan for purchasing drugs illegally
Time of Update: 2021-10-01
A pharmacy in Changchun, Jilin Province purchased drugs illegally and was fined 220,000 yuan .
According to the information in the administrative penalty decision, on April 22, 2021, the Jilin Provincial Drug Administration received a clue that the e-commerce department of Changchun Tianyi Pharmacy Chain Co.
-
Haichuang Pharmaceutical's CD44v6 inhibitor for gastrointestinal tumors is accepted for clinical application in China
Time of Update: 2021-10-01
Text|Pharmaceutical Mission HillsRecently, Haichuang Pharmaceuticals announced that the company has introduced a potential "first-in-class" new drug under development from Germany's amcure GmbH, the clinical trial application of HP558 injection has been formally approved by the National Food and Drug Administration (NMPA) of China Accept .
-
Starting from September 20th, 61 medicines in Tianjin have been reduced in price!
Time of Update: 2021-10-01
According to the statistics of contracted purchases in Tianjin, it is estimated that 265 million yuan of medicine purchase costs can be saved each year, which will effectively reduce the burden of medication for patients .
-
Insulin national procurement is about to start, these companies will be greatly affected
Time of Update: 2021-10-01
After the relevant pharmaceutical companies win the bid, they often need to increase their production capacity to meet market demand; in this context, more efficient and safer insulin production equipment is also required.
-
The development of the TCM industry continues to improve, and the TCM equipment industry will also usher in opportunities
Time of Update: 2021-10-01
Industry analysts believe that benefiting from favorable policies, the continued development of the traditional Chinese medicine market, and the increasing demand for patients, although the overall size of the Chinese medical device market in my country was not large in the past, the scale of this market in my country has begun to show up.
-
Anke Biological Growth Hormone Approved for New Indication for Treatment of Idiopathic Short Stature
Time of Update: 2021-10-01
Text|Pharmaceutical Mission HillsOn September 13, China's National Food and Drug Administration (NMPA) announced that Anke Biotech's newly-declared application for the marketing authorization of recombinant human growth hormone for injection for the treatment of idiopathic short stature (ISS) indications has been officially approved .
-
After domestically-made innovative drugs have entered the medical insurance one after another, manufacturers are facing two major challenges!
Time of Update: 2021-10-01
Recently, Tofflon also mentioned in its response to investors in the disclosed investor relations activity record sheet that domestically-made innovative drugs have entered medical insurance one after another, prompting downstream pharmaceutical companies to pay more attention to operating costs and the stability of the supply chain of production equipment and related materials.
-
Wise Pharma's business spans comparable to WuXi AppTec. Why is it the second-to-last in the industry?
Time of Update: 2021-10-01
Major shareholders' equity after the acquisition of Ruizhi Chemical in 2018Source: Wise Pharmaceutical Announcement ContentIn June 2019, Quantum Biology announced that in order to be more conducive to the company's strategic development and personal needs, the former chairman Zeng Xianjing resigned as chairman, and Huixin was elected as the new chairman by the company's board of directors .
-
Livzon Pharmaceutical's application for drug registration of triptorelin acetate microspheres for injection has been accepted
Time of Update: 2021-10-01
The company's application for triptorelin acetate microspheres for injection The registration and marketing authorization of domestically produced drugs was accepted by the China Food and Drug Administration .
The company is the first domestic enterprise to complete the clinical trials of triptorelin long-acting sustained-release preparations and apply for marketing authorization .
-
Under the multiple pressures of centralized procurement and foreign investment, where is the way out for local pharmaceutical companies?
Time of Update: 2021-10-01
On the one hand, under the background of normalization of centralized procurement, drug price reduction has become a trend, the industry is facing innovation and transformation, a group of small and medium-sized enterprises will face the situation of elimination, and the overall market competition will become more fierce; on the other hand, since China joined ICH in 2017, Mutual recognition of data has enabled local pharmaceutical companies to enjoy ICH dividends.
-
Zidoramivudine Tablets, a subsidiary of Northeast Pharmaceuticals, obtained a drug registration certificate
Time of Update: 2021-10-01
On September 14, Northeast Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, First Pharmaceutical Zidoramidivudine Tablets, had recently received the "Drug Registration C
-
Li Keqiang presided over an executive meeting of the State Council to review and approve the "14th Five-Year Plan" National Medical Security Plan
Time of Update: 2021-10-01
Premier Li Keqiang of the State Council presided over an executive meeting of the State Council on September 15 to deliberate and approve the "14th Five-Year" National Medical Security Plan, deploy and improve the medical insurance system to better meet the needs of the people for medical drugs; pass the "Groundwater Management Regulations (Draft)" to strengthen Conservation and protection of groundwater resources .
-
The domestic rare disease industry has huge development potential, and the market may exceed 60 billion yuan in 2030
Time of Update: 2021-10-01
The industry predicts that according to the current industry development trend, as domestic pharmaceutical companies continue to make efforts in the rare disease drug market in the future, the market potential will continue to grow substantially .
-
To Biao Yangzijiang and Hengrui!
Time of Update: 2021-10-01
There are 16 manufacturers of dexmedetomidine hydrochloride injection, of which 14 companies have been reviewed by Yangtze River Pharmaceutical Group, Jiangsu Hengrui Pharmaceutical, Nanjing Zhengda Tianqing Pharmaceutical, and Hunan Kelun Pharmaceutical; dexmedetomidine hydrochloride There are only two manufacturers of sodium chloride injection, Jiangsu Hengrui Pharmaceutical and Chengdu Better Pharmaceutical, both of which have been approved for imitation of category 3 and are deemed to have been reviewed .
-
11 companies were interviewed, unlicensed doctors were fined one million...It’s time for the "medical beauty fever" to cool down
Time of Update: 2021-10-01
In addition, the Zhejiang Provincial Health Commission recently reported a typical case of illegal medical aesthetics.
There were 761 illegal cases involving medical cosmetology institutions, with a fine of 8.
